Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 8/21/2025

Gastrointestinal Adverse Effects of Colchicine

Introduction to Colchicine Therapy

  • Colchicine is used to treat various conditions, including gout and Familial Mediterranean Fever (FMF), with recommended doses varying by condition, such as 1.0-1.5 mg/day for FMF and 0.5-0.6 mg three times daily for gout, as recommended by the American College of Rheumatology and the European Society of Cardiology 1, 2

Dosage and Efficacy

  • Low doses of colchicine (1.2 mg followed by 0.6 mg after one hour) are as effective as high doses and have fewer gastrointestinal adverse effects, with diarrhea occurring in approximately 23% of patients with low doses and up to 77% with high doses, as recommended by the American College of Physicians 3
  • For gout, lower doses (0.5-0.6 mg three times daily) may be sufficient, and consider single daily dosing to improve compliance, but divided doses may reduce side effects, as suggested by the European Society of Cardiology 2
  • The EULAR guidelines suggest using colchicine at low doses (0.5-0.6 mg/day) in patients with gout and cardiovascular disease, as it has shown cardiovascular benefits rather than risks 4, 2

Adverse Effects

  • Diarrhea is the most frequent adverse effect, occurring in approximately 23% of patients with low doses and up to 77% with high doses 3
  • Colchicine can cause gastrointestinal symptoms such as diarrhea, nausea, vomiting, and abdominal pain, which can be dose-dependent and may limit the ability to achieve therapeutic doses, as noted by the American College of Rheumatology 1
  • The European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy lists the main adverse effects of colchicine as diarrhea, nausea, vomiting, abdominal discomfort, and blood dyscrasias 5, 2

Monitoring and Management

  • Regular monitoring of complete blood counts, liver function tests, and renal function is recommended, with follow-up more frequently at initial diagnosis, when disease is unstable, and in patients with renal impairment, as recommended by the American College of Rheumatology and the European Society of Cardiology 1, 6, 7, 8
  • If side effects occur, consider temporary reduction of dairy products, split doses to reduce peak concentrations, dose reduction, use of antidiarrheal and spasmolytic agents, and gradual reintroduction of the regular dose once symptoms resolve, as suggested by the American College of Rheumatology 1
  • Close monitoring for myalgia, weakness, or elevated creatine kinase is necessary, particularly when combined with statins, as recommended by the American College of Cardiology 7

Contraindications and Precautions

  • Colchicine should be avoided or used with extreme caution in patients with severe renal impairment (creatinine clearance <15 mL/min), severe hepatic impairment, patients taking strong CYP3A4 inhibitors, and blood dyscrasias, as recommended by the European Society of Cardiology and the American College of Rheumatology 9, 1, 8
  • Alternative treatments, such as oral corticosteroids, intra-articular corticosteroid injections, or IL-1 inhibitors, should be considered when colchicine is contraindicated, as suggested by the European Society of Cardiology 8

Drug Interactions

  • CYP3A4 inhibitors, such as macrolide antibiotics (clarithromycin, erythromycin), antifungals (ketoconazole), protease inhibitors (ritonavir), and P-glycoprotein inhibitors (cyclosporine, verapamil), can increase colchicine levels by 200-300%, as noted by the American College of Rheumatology and the European Society of Cardiology 1, 8
  • Statins, particularly atorvastatin and simvastatin, can increase myopathy risk when combined with colchicine, with a moderate strength of evidence, as recommended by the American Heart Association 7
  • Rosuvastatin, fluvastatin, and pitavastatin are safer statin options when combined with colchicine, as suggested by the American Heart Association 7

Special Populations

  • Colchicine can be safely used in patients with congestive heart failure (CHF) for the treatment of gout, but requires monitoring and dose adjustments in certain situations, as recommended by the European Society of Cardiology and the American College of Rheumatology 10, 11, 1
  • Colchicine dose should be reduced in patients with renal impairment to prevent accumulation and toxicity, starting at 0.3 mg/day in severe renal impairment, as recommended by the American College of Rheumatology and the European Society of Cardiology 1, 8

Long-Term Therapy and Cardiovascular Benefits

  • Regular assessment every 6 months is recommended for patients on long-term therapy, with more frequent monitoring during the first year of treatment and in patients with renal impairment, as suggested by the American College of Rheumatology and the European Society of Cardiology 1, 8
  • Colchicine has been shown to have cardiovascular benefits, with trials like COLCOT and LODOCO2 demonstrating reductions in cardiovascular events at low doses (0.5mg daily), as noted by the EULAR guidelines and the European Society of Cardiology 4, 2
  • The European Society of Cardiology recommends considering losartan as an antihypertensive agent in patients with gout and hypertension due to its additional uricosuric properties, as suggested by the European Society of Cardiology 2

REFERENCES

8

Colchicine Use in Patients with Renal Impairment [LINK]

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025